PATENT CLAIM ANALYSIS

Application Number: 15986295
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "488000"]

Abstract:
The invention contemplates novel materials as anticonvulsant agents.

Claim (Index 11):
A method of treatment of a neurological disease or disorder, the method comprising administering to a subject in need of such treatment an effective amount of a compound selected from the group consisting of 3-methyl-2-propylpentyl (4-sulfamoylphenyl)carbamate (1); 2-ethylhexyl (4-sulfamoylphenyl)carbamate (2); 2-propylpentyl (4-sulfamoylphenyl)carbamate (3); 3,3-dimethylbutyl (4-sulfamoylphenyl)carbamate (4); phenethyl (4-sulfamoylphenyl)carbamate (5); 2-ethylbutyl (4-sulfamoylphenyl)carbamate (6); 2,4,4-trimethylpentyl (4-sulfamoylphenyl)carbamate (7); 2,4-dimethylpentan-3-yl (4-sulfamoylphenyl)carbamate (8); 3-methylpentan-2-yl (4-sulfamoylphenyl)carbamate (9), 3-methylpentyl(4-sulfamoylphenyl)carbamate (10) and sec-butyl(4-sulfamoylphenyl)carbamate (11).

Metadata:
- Claim Count in Document: 3.0
- Percentile: 93.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12527707', '13499486', '10547299', '14383803', '12666703']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7115059354467418
- 35 USC 102 Novelty (BERT): 0.5122186037287749
- Combined Prediction Score: 0.6915772022749451
- Mean Citation Score: 220.543934
- Max Citation Score: 230.04391
- Similarity Product: 143.6275476036954

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test